Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

House Bill May Target Drugmakers' Advertising Tax Breaks
Rep. Charles Rangel, D-N.Y., says the House Ways and Means Committee may seek to raise money for health reform by imposing a $37 billion tax on drugmaker"s advertisements, Bloomberg reports: "As lawmakers seek ways to pay for a health-care overhaul, "one thing that"s not off the table is you can pick up $37 billion knocking out the deduction for advertising" for prescription drugs,"" Rangel said. The idea is among several proposals by Democratic legislators to raise reform money (Donmoyer, 6/16).
generic viagra online
Team Develops DNA Compounds That Could Help Treat Lupus
A research team led by a University of Iowa investigator has generated DNA-like compounds that effectively inhibit the cells responsible for systemic lupus erythematosus -- the most common and serious form of lupus. There currently is no cure for this chronic autoimmune condition that damages the skin, joints and internal organs and affects an estimated one million Americans.
News of the day
96-Week MERIT ES Analysis Shows Efficacy Of Pfizer's HIV/AIDS Treatment Celsentri/Selzentry (Maraviroc) In Treatment-Naç¯ve HIV Patients
At 96-week follow up, data from the MERIT ES analysis show that treatment-naç¯ve HIV patients taking Celsentri/Selzentry (maraviroc), in combination with Combivir® (zidovudine/lamivudine) experienced comparable virologic suppression to undetectable levels and significantly greater increases in CD4 T-cell count through 96-weeks, compared to patients taking efavirenz in combination with zidovudine/ lamivudine. The data also show the favorable tolerability of Celsentri/Selzentry, which was associated with fewer discontinuations due to adverse events.1
Endocrinology

Daiichi Sankyo And MorphoSys Expand Collaboration With Two New Cancer-Related Antibody Programs

MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime Standard Segment, TecDAX) announced the start of a further two oncology-focused therapeutic antibody programs within its collaboration with DAIICHI SANKYO COMPANY, LIMITED (TSE: 4568, hereinafter Daiichi Sankyo). By exercising two options available under the parties" existing agreement, Daiichi Sankyo has selected two new target molecules against which MorphoSys will generate antibodies using its proprietary HuCAL technology. Daiichi Sankyo will carry out pre-clinical and clinical development and has worldwide marketing rights for all resulting products. MorphoSys receives exclusive license fees and stands to receive milestones and royalties for the therapeutic antibody programs, as per the terms of the companies" existing agreement. Further financial details were not disclosed. "The addition of these new oncology programs promises to strengthen still further our partnered antibody pipeline", commented Dr. Simon Moroney, CEO of MorphoSys. "We look forward to working with Daiichi Sankyo on the programs, and making progress towards our declared goal of establishing a broad therapeutic pipeline of HuCAL-based antibody drugs." The two companies have been engaged in joint application of MorphoSys"s advanced phage display and human antibody library technologies since March 2006. In March 2008, Daiichi Sankyo exercised its option to extend the contracting period until March 2011. Today, the collaboration encompasses four active therapeutic antibody programs. In May 2008, Daiichi Sankyo further strengthened its pipeline of novel targeted therapeutics in oncology by acquiring the German biotechnology company U3 Pharma AG. The cancer-related target molecules, which build the basis for the HuCAL-based programs, were part of U3 Pharma"s portfolio. Daiichi Sankyo and MorphoSys AG


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009